HEPION PHARMACEUTICALS, INC. Deferred Tax Assets, Valuation Allowance
HEPION PHARMACEUTICALS, INC. (HEPA) had Deferred Tax Assets, Valuation Allowance of $45.49 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $45.49M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $44.58M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $44.54M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $31.11M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $45.49M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $44.58M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $44.54M 10-K · filed 2025-04-08 | |
| 2022-12-31 | $31.11M 10-K · filed 2024-04-16 | |
| 2021-12-31 | $19.05M 10-K · filed 2023-04-10 | |
| 2020-12-31 | $10.24M 10-K · filed 2022-04-08 | $26.81M 10-K · filed 2021-03-31 |
| 2019-12-31 | $7.71M 10-K · filed 2022-04-08 | $20.82M 10-K · filed 2020-05-14 |
| 2018-12-31 | $19.48M 10-K · filed 2020-05-14 | $19.35M 10-K · filed 2019-03-14 |
| 2017-12-31 | $16.04M 10-K · filed 2019-03-14 | |
| 2017-06-30 | $20.96M 10-KT · filed 2018-03-26 | |
| 2016-06-30 | $14.42M 10-KT · filed 2018-03-26 | |
| 2015-06-30 | $6.16M 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |